Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
BioConferenceLive

Cell Imaging System Emphasizes Speed and Sensitivity

By BiotechDaily International staff writers
Posted on 26 Dec 2012
The most recent version of a high-speed cell imaging system designed for both screening and research has now been released to the biotech and life science markets.

The GE Healthcare (Chalfont St. Giles, United Kingdom) IN Cell Analyzer 2200 is a high-speed, flexible, modular imaging system suitable for both investigative microscopy and automated high-content screening of organelles, cells, tissues, and whole organisms.

For screening applications a combination of proprietary optics, a choice of large or standard chip camera, and fast hardware and software autofocus capabilities deliver accurate, high-speed imaging. A bright light source reduces exposure times to further maximize speed without compromising image quality and cell health while the rapid image restoration options allow confocal-like images to be obtained.

A variety of innovative imaging features and a wide range of objectives (2 to 100 times) gives exceptional flexibility for real-time research use. The manual microscope mode allows manipulation of images at full size and resolution, in and out zoom capability, and manual settings adjustments (e.g., filters, objectives, and z-height).

The instrument can image a two-colored 96-well plate assay in about 150 seconds and a one-color 1,536 plate in less than 20 minutes. This speed is possible due to a bright, seven-wavelength solid-state light source and scientific-grade CMOS camera coupled with an optimized stage and efficient, easy-to-use control software. Furthermore, the system is designed to maximize the quantitative accuracy of captured images for any sample type, including image restoration for dim samples.

Related Links:

GE Healthcare



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: In the liver tissue of obese animals with type II diabetes, unhealthy, fat-filled cells are prolific (small white cells, panel A). After chronic treatment through FGF1 injections, the liver cells successfully lose fat and absorb sugar from the bloodstream (small purple cells, panel B) and more closely resemble cells of normal, non-diabetic animals (Photo courtesy of the Salk Institute for Biological Studies).

Fibroblast Growth Factor 1 Treatment Restores Glucose Control in Mouse Diabetes Model

A "vaccine" based on the metabolic regulator fibroblast growth factor 1 (FGF1) removed the insulin resistance that characterizes type II diabetes and restored the body's natural ability to manage its glucose... Read more

Drug Discovery

view channel
Image: Molecular rendering of the crystal structure of parkin (Photo courtesy of Wikimedia Commons).

Cinnamon Feeding Blocks Development of Parkinson's Disease in Mouse Model

A team of neurological researchers has identified a molecular mechanism by which cinnamon acts to protect neurons from damage caused by Parkinson's disease (PD) in a mouse model of the syndrome.... Read more

Therapeutics

view channel
Image: This type of electronic pacemaker could become obsolete if induction of biological pacemaker cells by gene therapy proves successful (Photo courtesy of Wikimedia Commons).

Gene Therapy Induces Functional Pacemaker Cells in Pig Heart Failure Model

Cardiovascular disease researchers working with a porcine heart failure model have demonstrated the practicality of using gene therapy to replace implanted electronic pacemakers to regulate heartbeat.... Read more

Business

view channel

Cancer Immunotherapy Sector Predicted to Surge to USD 9 Billion Across Major Pharma Through 2022

The immunotherapy market will experience substantial growth through 2022, increasing from USD 1.1 billion in 2012 to nearly USD 9 billion in 2022 (corresponding to 23.8% annual growth) in the United Kingdom, United States, France, Germany, Italy, Spain, and Japan, according to recent market research. This notable growth... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.